# Azilsartan medoxomil

## Edarbi 40mg

| TAH Drug Code      | [OEDA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEDA                                                                                                                                                                                      |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of hypertension; may be used alone or in combination with other antihypertensives.                                                                                                                                                             |
| Dosing             | HTN Initial: 20-40 mg QD; titrate up to maximum 80 mg QD                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to azilsartan medoxomil or any component of the formulation; concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR <60 mL/minute/1.73 m2).                                               |
| Adverse Effects    | Hypotension, orthostatic hypotension, Dizziness, fatigue, Diarrhea, nausea, Decreased hemoglobin, decreased hematocrit, decreased red blood cells, leukopenia (rare), thrombocytopenia (rare), Muscle spasm, weakness, Increased serum creatinine, Cough |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/azilsartan-medoxomil-drug-information)                                                                                                                                                                      |

